March 11 (Reuters) - The U.S. FDA has declined to approve Viatris and Mapi Pharma's once-a-month injection for the treatment of relapsing forms of multiple sclerosis, the companies said on Monday. (Reporting by Sriparna Roy and Sneha S K in Bengaluru; Editing by Pooja Desai)
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
11.72 USD | -0.85% | +1.30% | +8.22% |
Apr. 18 | Viatris' Proposed Femoston, Duphaston UK Rights Divestment Being Considered, CMA Says | MT |
Apr. 18 | UK Regulator to Consider Undertakings for Theramex-Viatris Deal | MT |
Stocks mentioned in the article
Price
|
Change
|
5d. change
|
Capi.
| ||
---|---|---|---|---|---|
2,706 PTS | -1.45% | -1.34% | - | ||
11.72 USD | -0.85% | +1.30% | 13.92B | ||
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+8.22% | 13.92B | |
+33.43% | 700B | |
+26.43% | 569B | |
-5.12% | 358B | |
+19.59% | 330B | |
+4.89% | 287B | |
+14.32% | 236B | |
+5.79% | 202B | |
-9.49% | 197B | |
+4.26% | 161B |
- Stock Market
- Equities
- VTRS Stock
- News Viatris Inc.
- US FDA declines to approve Viatris's injection for multiple sclerosis